FDA Grants Two National Priority Vouchers
http://www.fda.gov/news-events/press-announcements/fda-grants-two-national-priority-vouchers

FDA Explores New Contracting Approach to Advance Public Health Innovation
http://www.fda.gov/news-events/press-announcements/fda-explores-new-contracting-approach-advance-public-health-innovation

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/olympus-announces-voluntary-corrective-action-single-use-ligating-device

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medinatura-new-mexico-inc-expands-voluntary-nationwide-recall-reboost-nasal-spray-and-include

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/stuffbynainax-llc-issues-voluntary-nationwide-recall-mr7-super-700000-dietary-supplement-due

FDA Takes Action to Improve Recall Effectiveness Following Infant Botulism Outbreak Investigation Linked to ByHeart Infant Formula
http://www.fda.gov/news-events/press-announcements/fda-takes-action-improve-recall-effectiveness-following-infant-botulism-outbreak-investigation

FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews
http://www.fda.gov/news-events/press-announcements/fda-eliminates-major-barrier-using-real-world-evidence-drug-and-device-application-reviews

FDA Proactively Awards National Priority Voucher Based on Strong Phase 3 Study Results
http://www.fda.gov/news-events/press-announcements/fda-proactively-awards-national-priority-voucher-based-strong-phase-3-study-results

FDA Approves Two Oral Therapies to Treat Gonorrhea
http://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat-gonorrhea

FDA Proposes Expanding Sunscreen Active Ingredient List
http://www.fda.gov/news-events/press-announcements/fda-proposes-expanding-sunscreen-active-ingredient-list